Use of FLT3 ligand for enhancing immune responses in RNA immunization

US9486519B2 · kind B2 · utility

Assignees

• BioNTech AG · DE
• TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

• Ugur Sahin · Mainz, DE
• Ozlem Tureci · Homburg, DE
• Sebastian Kreiter · Mainz, DE
• Abderraouf Selmi · Mainz, DE

Key dates

• Filing date: Dec 9, 2009
• Grant date: Nov 8, 2016
• Expiry date: Aug 20, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to supplying vaccine RNA to cells. The invention relates in particular to a common use of vaccine RNA and Flt3 ligand for inducing, creating or enhancing an immune response when administered to animals (including humans).